Latest News
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial
7 January 2026 - Biotechnology company Compass Pathways plc (Nasdaq: CMPS) announced on Wednesday that the U.S. Food and Drug Administration has accepted its Investigational New Drug application for COMP360 in post-traumatic stress disorder, enabling...
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
7 January 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, confirmed on Wednesday that it has completed its cash tender offer for all outstanding shares of Cidara Therapeutics Inc (Nasdaq:CDTX), ...
GSK wins European Commission approval for Shingrix prefilled syringe
7 January 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Wednesday that the European Commission has approved a prefilled syringe presentation of its shingles vaccine Shingrix, providing a simplified administration option...
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
7 January 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq/AIM: HCM) (HKEX: 13) on Wednesday reported positive topline results from the Phase III registration part of the ESLIM-02 trial of sovleplenib in adult patients with warm anti...
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
7 January 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) on Wednesday reported positive phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hep...